新光药业(300519) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 was ¥70,769,147.70, a decrease of 16.81% compared to ¥85,070,762.04 in the same period last year[7] - Net profit attributable to shareholders was ¥27,303,243.40, down 16.17% from ¥32,569,749.28 year-on-year[7] - Basic earnings per share decreased by 15.00% to ¥0.17 from ¥0.20 in the previous year[7] - Operating profit was 32.13 million yuan, down 16.17% compared to the same period last year[19] - Net profit attributable to shareholders was 27.30 million yuan, also a decline of 16.17% year-on-year[19] - Total operating revenue for Q1 2020 was CNY 70,769,147.70, a decrease of 16.9% compared to CNY 85,070,762.04 in the same period last year[37] - Net profit for Q1 2020 was CNY 27,303,243.40, representing a decline of 16.3% from CNY 32,569,749.28 in Q1 2019[39] - Earnings per share for Q1 2020 was CNY 0.17, compared to CNY 0.20 in the same period last year[40] Cash Flow and Assets - The net cash flow from operating activities was ¥35,758,819.24, a decline of 5.66% compared to ¥37,905,395.67 in the same period last year[7] - Cash flow from operating activities for Q1 2020 was CNY 35,758,819.24, a decrease of 5.7% from CNY 37,905,395.67 in Q1 2019[42] - Cash inflow from operating activities totaled CNY 79,524,630.24, compared to CNY 91,440,225.29 in the same period last year[42] - The company's cash and cash equivalents increased to CNY 424,383,948.59 from CNY 407,352,701.82, reflecting a growth of approximately 5.04%[34] - The cash balance at the beginning of the period was 407,352,701.82 CNY[44] - The net cash flow from investment activities was -18,727,572.47 CNY, a decrease from 12,897,726.42 CNY in the previous year[44] Assets and Liabilities - Total assets increased by 2.72% to ¥884,581,882.37 from ¥861,130,616.44 at the end of the previous year[7] - Total current assets reached CNY 725,559,685.60, up from CNY 698,407,571.08, indicating an increase of about 3.36%[34] - The inventory decreased to CNY 44,342,618.34 from CNY 49,235,383.40, representing a decline of approximately 10.5%[34] - Total liabilities as of Q1 2020 were CNY 57,389,770.20, a decrease from CNY 61,420,403.74 in the previous year[37] - The total liabilities were 61,420,403.74 CNY, while total equity was 799,710,212.70 CNY[48] Shareholder Information - The top shareholder, Wang Yuejun, holds 38.25% of the shares, totaling 61,200,000 shares[11] - The total number of ordinary shareholders at the end of the reporting period was 13,428[11] - Net assets attributable to shareholders rose by 3.44% to ¥827,192,112.17 from ¥799,710,212.70 at the end of the previous year[7] - Total equity attributable to shareholders was CNY 827,192,112.17, an increase from CNY 799,710,212.70 in Q1 2019[39] Research and Development - Research and development expenses were reduced by 48.52% to 2.39 million yuan[17] - Research and development expenses for Q1 2020 were CNY 2,387,487.44, down 48.7% from CNY 4,637,721.94 in Q1 2019[37] - The construction of the R&D quality inspection center has been delayed, with the expected completion date pushed from December 2019 to December 2021[26] Government Support and Investment - The company received government subsidies amounting to ¥416,375.76 during the reporting period[8] - Total fundraising amount was 211.67 million yuan, with 35.06 million yuan invested in the current quarter[25] - The company received 30,000,000.00 CNY related to investment activities, down from 50,000,000.00 CNY in the previous year[44] Operational Stability - The company has not experienced significant changes in its top five suppliers or customers, indicating stable procurement and sales dynamics[20][21] - The company is actively managing risks associated with the COVID-19 pandemic, ensuring stable supply and customer relations[21][22] - The company has committed to a project for the production line of Huangqi Shengmai drink with an annual capacity of 220 million units, with a total investment of CNY 21,178 million[26] - There were no significant changes in the feasibility of the investment projects, and no violations of external guarantees were reported during the reporting period[28][29] Compliance and Standards - The company is implementing new revenue and leasing standards starting from 2020[46] - The company has not made any adjustments to the retained earnings for the first execution of the new standards[48] - The company has not yet audited the first quarter report[49]